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List of abbreviations  40 
Abbreviation  Spelling  
A Alanine 
ACE Angiotensin converting enzyme 
ACP Amorphous calcium phosphate 
ACPF Amorphous calcium phosphate fluoride 
Ala Alanine 
Arg Arginine 
BAP Bioactive peptide 
BCAA Branched-chain amino acids 
BMI Body mass index 
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Tr-1 Type 1-regulatory T 
Trp Tryptophan 
Tyr Tyrosine 
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Val Valine 
W Tryptophan 
WHO World Health Organization 
WP Whey protein 
WPC Whey protein concentrate 
WPH Whey protein hydrolysate 
WPI Whey protein isolate 
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Zn Zinc 
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Abstract 43 
Milk proteins are a good source of bioactive peptides (BAPs). BAPs can positively affect various 44 
health biomarkers in vitro. The role of milk protein-derived BAPs in humans was reviewed 45 
herein. To date, a limited number of BAPs have been identified in the gastrointestinal tract of 46 
humans and in the circulation at concentrations which may be sufficient to mediate in vivo 47 
bioactivity. While the outcomes of several human intervention studies have shown promising 48 
results, some studies have failed to demonstrate additional health benefits. This may be related to 49 
a low potency and bioavailability of the BAPs evaluated as well as confounding factors (i.e. 50 
genotype, health status and other sources of inter-individual variability). Universal guidelines for 51 
the evaluation of BAPs in humans such as adequately powered double-blind randomised clinical 52 
trials are needed. 53 
 54 
 55 
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1 Introduction 59 
Milk is the primary source of nutrients for young mammalians. It is recognised as being 60 
nutritionally balanced and has therefore attracted a lot of scientific interest over the years. 61 
Various properties of intact milk proteins have been reported including satiating, antimicrobial, 62 
mineral binding, antilipidaemic and anticancer properties (Anderson & Moore, 2004; Chatterton, 63 
Smithers, Roupas, & Brodkorb, 2006; Clare & Swaisgood, 2000; Cross, Huq, O'Brien-Simpson, 64 
et al., 2007; Nakamura et al., 2013). Following their digestion in the gastrointestinal tract (GIT), 65 
milk proteins are broken down to smaller components consisting of free amino acids and 66 
peptides, which may be used as the building blocks for a wide range of proteins in the body 67 
(Wada & Lönnerdal, 2014). Over the past few decades, it has been shown that specific protein 68 
fragments, called bioactive peptides (BAPs), may beneficially modulate certain health related 69 
biomarkers, at least in vitro. To date, there have been many studies demonstrating the potentially 70 
beneficial effect in vitro of food protein-derived BAPs on biomarkers associated with the 71 
metabolic syndrome and bone health (Hernández-Ledesma, García-Nebot, Fernández-Tomé, 72 
Amigo, & Recio, 2014; Panchaud, Affolter, & Kussmann, 2012; Udenigwe & Aluko, 2012). 73 
These include BAPs with antihypertensive, antidiabetic, antiobesity, antioxidant, 74 
immunomodulatory and mineral binding properties (FitzGerald & Meisel, 2003b; Korhonen & 75 
Pihlanto, 2006; Nongonierma & FitzGerald, 2012; Pihlanto, 2006; Power, Jakeman, & 76 
FitzGerald, 2013). In some instances, the in vivo effects of these milk protein-derived BAPs have 77 
been demonstrated in small animals (Bernabucci & Nardone, 2014; García-Tejedor et al., 2014; 78 
Gaudel et al., 2013; Sánchez-Rivera et al., 2014; Schellekens et al., 2014; Yamada et al., 2015) 79 
and also in humans (Akhavan, Luhovyy, Brown, Cho, & Anderson, 2010; Geerts et al., 2011; 80 
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Jauhiainen et al., 2009; Jauhiainen et al., 2010; Morifuji et al., 2010; Usinger, Ibsen, et al., 2010; 81 
Xu, Qin, Wang, Li, & Chang, 2008). 82 
Several studies have suggested that milk protein-derived BAPs may be used as 83 
preventative/prophylactic agents to alleviate symptoms of various diseases in humans. Although 84 
various drugs exist to cure/slow down the progress of specific diseases in humans, their side-85 
effects may sometimes outweigh their benefits (Fekete, Givens, & Lovegrove, 2015; Li-Chan, 86 
2015; Saadi, Saari, Anwar, Hamid, & Ghazali, 2015). In this context, food protein-derived 87 
peptides and specifically milk protein-derived BAPs have potential as natural alternatives to 88 
drugs for disease management (Carrasco-Castilla, Hernández-Álvarez, Jiménez-Martínez, 89 
Gutiérrez-López, & Dávila-Ortiz, 2012; Li-Chan, 2015; Saadi et al., 2015; Zambrowicz, 90 
Timmer, Polanowski, Lubec, & Trziszka, 2013). For example, no cytotoxic effects have been 91 
shown in small animals following the consumption of angiotensin converting enzyme (ACE) 92 
inhibitory peptides Ile-Pro-Pro and Val-Pro-Pro (Bernard, Nakamura, Bando, & Mennear, 2005; 93 
Maeno, Nakamura, Mennear, & Bernard, 2005; Ponstein-Simarro Doorten, vd Wiel, & Jonker, 94 
2009). Similarly, the antimicrobial (lactoferrin- LF f(1-11)) peptides have been evaluated as 95 
being safe for human consumption (Brouwer, Rahman, & Welling, 2011; van der Velden, van 96 
Iersel, Blijlevens, & Donnelly, 2009). 97 
Milk protein-derived BAPs are not biologically active when present within the parent protein. 98 
They may be released by different means which include enzymatic hydrolysis of the proteins 99 
using various proteolytic/peptidolytic preparations, microbial fermentation, chemical or physical 100 
hydrolytic means and also naturally during the gastrointestinal (GI) digestion of milk proteins 101 
(Nongonierma & FitzGerald, 2011; Saadi et al., 2015). Milk protein-derived BAPs are therefore 102 
naturally present in a wide range of dairy products and foods containing dairy-based ingredients. 103 
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Depending on their sequence, these BAPs may reach the small intestine intact and be absorbed as 104 
is or they may be degraded by GI enzymes or serum peptidases in the circulation. Several studies 105 
have investigated the stability and bioavailability of milk BAPs, mainly following in vitro 106 
simulated gastrointestinal digestion (SGID) treatments (Nongonierma & FitzGerald, 2013; 107 
Stuknytė, Cattaneo, Masotti, & De Noni, 2015; Walsh et al., 2004) or permeation through Caco-108 
2 cell monolayers (Picariello et al., 2013; Quirós, Dávalos, Lasunción, Ramos, & Recio, 2008; 109 
Shimizu, Tsunogai, & Arai, 1997; Vermeirssen et al., 2002). However, only a limited number of 110 
studies have been carried out in relation to the stability and bioavailability of BAPs in humans 111 
(Foltz et al., 2007; Jauhiainen et al., 2009; Jauhiainen et al., 2007). This may, in some instances, 112 
be related to analytical limitations associated with the detection of peptides and notably short 113 
peptides (Le Maux, Nongonierma, & FitzGerald, 2015; Panchaud et al., 2012) in relatively 114 
complex physiological fluids. In addition, because BAPs are naturally found within the body, 115 
notably in digestate fluids (Barbé et al., 2014; Boutrou et al., 2013; Chabance et al., 1998), the 116 
serum (Foltz et al., 2007) and different tissues (Jauhiainen et al., 2007) at relatively low levels (< 117 
10 ppm), it may in certain cases be challenging to demonstrate the contribution of specific BAP 118 
sequences to a target bioactive property. Quantification of a number of casein (CN)-derived 119 
peptides in the jejunum of human subjects showed that their average concentration was 17 and 120 
900 µM for the opioid peptide -casomorphin-7 (-CN f(60-66)) and the ACE inhibitory peptide 121 
-CN f(108-113), respectively. The half maximal inhibitory concentrations of -casomorphin-7 122 
and -CN f(108-113) were estimated at 100 µM (opioid agonist activity) and 423 µg L-1 (0.6 123 
µM, ACE inhibition), respectively. This led the authors to conclude that these peptides were 124 
likely to display a biological activity in vivo (Boutrou et al., 2013). Interestingly, to date, no 125 
short peptides (di- and tripeptides) have been detected in the GIT of humans. This may be due to 126 
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analytical limitations associated with MS peptide identification (Boutrou, Henry, & Sanchez-127 
Rivera, 2015). 128 
The bioactive response of a single peptide may be masked by the presence of other components 129 
originating from the diet (Hansen, Sandström, Jensen, & Sørensen, 1997). Furthermore, the 130 
difficulty of defining adequate control subjects has often been highlighted in human intervention 131 
studies. It appears easier to obtain more relevant controls with animals as their diet can be more 132 
tightly regulated than that of human subjects. Moreover, a number of studies have highlighted 133 
the contribution of confounding factors (variables which are not controlled) such as genotype on 134 
the biological/physiological outcome(s) of dairy-derived dietary components in humans 135 
(Abdullah et al., 2014; Cicero, Gerocarni, Laghi, & Borghi, 2011; Fekete, Givens, & Lovegrove, 136 
2013). This may explain the inter-individual variability of responses to specific interventions 137 
with bioactive components. In many instances, a direct correlation between ingestion of specific 138 
milk protein-derived BAPs and their beneficial effects on specific health biomarkers appears 139 
difficult to establish. Consequently it has become challenging for different regulatory bodies to 140 
grant health claim approval to specific ingredients. This is notably the case for milk protein-141 
derived opioid and ACE inhibitory peptides from milk proteins even though these BAPs have 142 
been quite extensively studied (De Noni et al., 2009; EFSA, 2010, 2011). 143 
Different meta-analyses have been performed on human trial data obtained with milk protein-144 
derived BAPs. This is particularly the case for ACE inhibitory peptides (Cicero et al., 2011; 145 
Cicero, Aubin, Azais-Braesco, & Borghi, 2013; Fekete et al., 2013; Qin et al., 2013; Turpeinen, 146 
Järvenpää, Kautiainen, Korpela, & Vapaatalo, 2013; Xu et al., 2008) and 147 
caseinophosphopeptides (CPPs) (Yengopal & Mickenautsch, 2009). However, these meta-148 
analyses are very focused and do not take a general overview incorporating the potential 149 
 11 
 
multifunctional effects of milk protein-derived BAPs. Since it has been clearly demonstrated that 150 
BAPs can have multifunctional properties (Ballard et al., 2013; Mandal et al., 2014), it appeared 151 
essential to take a broader view when reviewing the scientific evidence in connection with the in 152 
vivo effects of milk protein-derived BAPs. Boutrou et al. (2015) have recently reviewed the 153 
BAPs originating from milk which have been identified in the intestinal contents of humans and 154 
animals. Although the presence of milk protein-derived BAPs has been demonstrated in the GIT 155 
and in the plasma of humans, it is still unclear if these peptides display a biological effect in vivo. 156 
Specific peptides are able to reach the blood circulation without being degraded and may be 157 
found in physiologically relevant amounts (Foltz et al., 2007). However, to our knowledge, only 158 
a limited number of reviews have critically assessed the effect of milk BAPs on metabolic health 159 
in humans (Artym & Zimecki, 2013; Hernández-Ledesma et al., 2014; McGregor & Poppitt, 160 
2013). The aim of this review was to assess current literature related to the manner in which 161 
different milk protein-derived BAP sequences may affect a wide range of health biomarkers in 162 
humans. Different biomarkers/targets which appear crucial in human health have been 163 
incorporated in the present review. The evidence linking the in vitro activity of milk protein-164 
derived BAPs and their physiological effects in humans will be discussed taking specific 165 
examples from ACE inhibitory, mineral binding, antidiabetic, satiating, immunomodulatory, 166 
opioid and antioxidant activities along with their role in nutrition for populations with specific 167 
needs. Finally, recommendations to improve human intervention studies with milk protein-168 
derived BAPs with health promoting effects will be suggested. 169 
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2 Milk protein-derived BAPs identified in the circulation of humans  170 
To date, there are limited number of scientific studies which have reported the presence of 171 
peptides in the circulation of humans (Chabance et al., 1995; Chabance et al., 1998; Foltz et al., 172 
2007; Gardner, 1983). Subsequent to ingestion of milk or dairy products, milk protein-derived 173 
peptides have been identified in biological fluids of humans including plasma, serum and milk 174 
(Foltz et al., 2007; Koch et al., 1988; Kost et al., 2009; Renlund et al., 1993; Righard, Carlsson-175 
Jonsson, & Nyberg, 2014) as outlined in Table 1. To date, the peptides identified in biological 176 
fluids from humans mostly originate from CNs. Dipeptides and peptides as large as 177 
caseinomacropeptide (CMP; 64 amino acid length) have been identified in the plasma, serum and 178 
milk of humans (Table 1). Some of the peptides detected in human plasma have previously been 179 
reported for their ACE inhibitory (Foltz et al., 2007) and opioid (Koch et al., 1988; Kost et al., 180 
2009; Renlund et al., 1993; Righard et al., 2014) properties. For example, the ACE inhibitory 181 
peptides Leu-Trp, Phe-Tyr, Ile-Tyr, Ile-Trp, Ala-Trp, Val-Tyr, Leu-Pro-Pro and Ile-Pro-Pro, 182 
were detected in the circulation of humans following the ingestion of a lactotripeptide (LTP) 183 
enriched yoghurt beverage (Foltz et al., 2007). CMP from bovine and human milk has also been 184 
detected in the plasma of newborns (Chabance et al., 1995). An average concentration of 16 and 185 
21 µg mL
-1
 of CMP was reported in the plasma of newborns fed with human milk and cow’s 186 
milk-based infant formula, respectively. The question remains whether these concentrations are 187 
sufficient to mediate a physiological response. The presence of intact CMP in the plasma of 188 
infants has been explained by the relatively higher permeability of their gut, the low level of 189 
proteolytic enzymes in their stomach and the inhibitory role of CMP on gastric secretion 190 
(Chabance et al., 1995). Other human studies have reported the detection of peptides in the 191 
plasma (Chabance et al., 1998). Fragments corresponding to s1-CN f(1-23), s1-CN f(1-21) and 192 
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-CN f(106-126) have been identified following the ingestion of milk or yoghurt by human 193 
subjects (Chabance et al., 1998). The low number of peptides found within the plasma compared 194 
to the GIT (Boutrou et al., 2013; Chabance et al., 1998) was attributed to the possible 195 
degradation of peptides which may occur following the hydrolytic action of GI enzymes and 196 
intestinal cell peptidases. Of the -CN peptides detected in the stomach, duodenum or plasma in 197 
the study of Chabance et al. (1998), a number have been reported to have antithrombic, 198 
antiaggregation and antihypertensive activities. 199 
A large number of studies have been conducted in small animals which have shown a 200 
physiological effect of milk protein-derived BAPs. Although only a few studies have been 201 
conducted in humans, this number has been on the increase for the last few years. This can be 202 
explained by the growing interest by the scientific, industrial and healthcare communities in the 203 
application of natural components for health enhancement. This is particularly relevant in the 204 
context where metabolic diseases and their associated complications are on the increase 205 
worldwide. BAPs from milk or other food proteins, alone, or in combination with drugs 206 
(Nongonierma & FitzGerald, 2015), may find application as natural alternatives to drugs to act as 207 
preventative agents of various diseases in humans (Li-Chan, 2015; Saadi et al., 2015). This could 208 
help avoid the side-effects seen with many drugs. The effects of milk protein-derived BAPs 209 
having antihypertensive, opioid, satiating and blood serum glucose regulating activities have 210 
been particularly studied in humans. However, in many cases, a direct link between in vitro and 211 
in vivo bioactivity is difficult to establish. 212 
 213 
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3 ACE inhibitory peptides 214 
Milk protein-derived antihypertensive peptides and particularly ACE inhibitory peptides have 215 
been evaluated in numerous human intervention studies (Fekete et al., 2013). This may be linked 216 
with the fact that cardiovascular diseases (CVDs) are the major cause of death in humans 217 
globally (WHO, 2013a). High blood pressure (BP) is a modifiable risk factor for CVD. 218 
Mechanisms other than ACE inhibition have also been reported as being associated with the 219 
observed hypotensive effects of milk BAPs (endothelin converting enzyme inhibition, opioid-220 
induced BP regulation, renin inhibition, immunomodulation and antioxidation) (Fekete et al., 221 
2013; Norris & FitzGerald, 2013). Three groups of milk BAPs with ACE inhibitory activity have 222 
been extensively evaluated in humans, these include the CN-derived LTPs (Ile-Pro-Pro and Val-223 
Pro-Pro commercialised as Evolus® and Ameal S®), Ser-Lys-Val-Tyr-Pro and the s1-CN-224 
derived C12 peptide (Phe-Phe-Val-Ala-Pro-Phe-Pro-Glu-Val-Phe-Gly-Lys) (Fekete et al., 2013). 225 
The LTPs appear to be the most studied peptides in humans to date (Fekete et al., 2015). A 226 
number of meta-analyses on LTPs are available in the scientific literature describing the main 227 
outcomes of the consumption of these peptides in humans (Cicero et al., 2011; Cicero et al., 228 
2013; Fekete et al., 2015; Qin et al., 2013; Turpeinen et al., 2013; Xu et al., 2008). 229 
The main mechanism of action involved in the BP reducing effect of the LTPs is thought to 230 
involve ACE inhibition, arginase inhibition (relevant to the nitric oxide system) and 231 
endothelium-derived hyperpolarization factor-related mechanisms (Turpeinen et al., 2013). A 232 
summary of the 6 meta-analyses carried out to date on the effect of LTPs on BP in humans is 233 
outlined in Table 2. Based on the inclusion criteria, in the most recent meta-analysis, 33 human 234 
interventions conducted between 1996 and 2012 were taken into account (Fekete et al., 2015). It 235 
was shown that the main outcome of the human interventions to date is a significant reduction in 236 
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systolic BP (SBP, -2.95 mmHg) and diastolic BP (DBP, -1.51 mmHg, Table 2) (Fekete et al., 237 
2015). Analysis of the subgroup characteristics allowed identification of various parameters 238 
which had a differential impact on BP. A higher reduction in SBP and DBP was seen in (a) 239 
subjects with higher baseline BP, (b) lower body mass index (BMI) and (c) younger age (Cicero 240 
et al., 2013; Fekete et al., 2015; Qin et al., 2013; Xu et al., 2008). The study design also affected 241 
the BP outcomes with a positive effect of BP reduction seen in studies (a)  8 weeks in duration, 242 
(b) carried out with a lower LTP dose ( 10 mg/day), (c) LTPs obtained by fermentation, (d) 243 
with a Japanese vs. European population and (e) double-blind randomised clinical trials (Cicero 244 
et al., 2011; Fekete et al., 2015; Qin et al., 2013; Turpeinen et al., 2013). The racial effects have 245 
been explained by both genetic differences and also environmental factors. Within the 246 
environmental factors, diet is thought to play an important role in the responsiveness of different 247 
populations. For instance, the lower consumption of milk/dairy products in Japan compared to 248 
Europe may, in part, explain the differences observed (Fekete et al., 2015). Other parameters 249 
may influence the greater decrease in BP seen in the Japanese population; these comprise factors 250 
which have been shown to positively impact on BP reduction, including a lower BMI and a 251 
lower LTP dose (7.57 vs. 11.68 mg/day for the Japanese and European populations, respectively) 252 
(Fekete et al., 2015). A higher responsiveness of Japanese subjects to drugs involving the renin–253 
angiotensin system and differences in the pharmacokinetics of the LTPs in Asians in comparison 254 
to Caucasians have also been proposed to explain these differences (Cicero et al., 2011). In 255 
addition, it has been suggested that peptides with different cis/trans conformations may have 256 
been employed in the different human studies and these may have a different biological activity 257 
(Fekete et al., 2015; Turpeinen et al., 2013). 258 
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All six meta-analyses showed a significant reduction in SBP and DBP in humans consuming the 259 
LTPs. However, the decrease in SBP and DBP was modest compared to that usually reported 260 
with BP reducing drugs (Baguet, Legallicier, Auquier, & Robitail, 2007). In a meta-analysis 261 
carried out on BP reducing drugs, it has been stated that a modest reduction of BP may positively 262 
impact on risk reduction of CVD. After a one year follow-up with BP reducing drugs, a 263 
reduction of the SBP (-10 mmHg) and DBP (-5 mmHg), was predicted to lower the risk of 264 
coronary artery disease and stroke by approximately 20 and 32%, respectively (Law, Morris, & 265 
Wald, 2009). Interestingly, the LTP Ile-Pro-Pro has been detected in the circulation of humans 266 
following ingestion of a LTP-enriched yoghurt beverage (Foltz et al., 2007). Significantly higher 267 
levels of Ile-Pro-Pro were detected after consumption of the LTP drink compared to the placebo 268 
(an isocaloric beverage), 897 ± 157 and 555 ± 0.09 pmol L
-1
, respectively. Furthermore, these 269 
levels were increased when the yoghurt was consumed with a meal (Foltz et al., 2007). Despite 270 
the detection of ACE inhibitory milk protein-derived peptides in human serum and the positive 271 
outcomes of several meta-analyses, the effects observed in humans on BP reduction are 272 
moderate. In addition, due to confounding factors in humans studies, conflicting results are found 273 
in the literature, making it difficult to conclude on the role of milk protein-derived BAPs as 274 
antihypertensive agents. 275 
4 Mineral binding peptides 276 
CPPs have been proposed to play a role in improving the bioavailability of dietary metal ions. It 277 
has been suggested that the mineral binding properties of CPPs are linked with a specific 278 
sequence, the “acidic motif”, i.e., Ser(P)-Ser(P)-Ser(P)-Glu-Glu (Bouhallab & Bouglé, 2004). To 279 
date, the relationship between CPP intake and Ca absorption has still not been clearly 280 
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demonstrated in the scientific literature (FitzGerald, 1998; FitzGerald & Meisel, 2003a; 281 
Hartmann & Meisel, 2007; Meisel & FitzGerald, 2003; Meisel & Frister, 1988; Pinto et al., 282 
2012). Owing to their anionic properties, CPPs are thought to be resistant to GI digestion (Kitts, 283 
2005). This may help explain the fact that they have been found in the GIT and faeces of rats and 284 
humans (Hartmann & Meisel, 2007; Kasai, Iwasaki, Tanaka, & Kiriyama, 1995). 285 
To date, most of the human studies carried out with CPPs in humans have focused on their teeth 286 
remineralising properties in the context of dental caries (for review, see: Nongonierma & 287 
FitzGerald, 2012; Pinto et al., 2012; Reynolds, 2008). Many studies concluded in a beneficial 288 
effect of CPPs on dental enamel remineralisation in humans. For dental applications, amorphous 289 
calcium phosphate (ACP), the precursor of hydroxyapatite, has been combined to CPPs to form 290 
CPP-ACP complexes. These complexes have been formulated in a dental ingredient, sold under 291 
the trade name Recaldent
TM
, aimed at remineralising the enamel surface and reducing the rate of 292 
enamel decalcification. Recaldent
TM
 is thought to increase Ca and phosphate solubility as well as 293 
hydroxide ion content (Azarpazhooh & Limeback, 2008; Cross, Huq, & Reynolds, 2007; 294 
Reynolds, 1998; Rose, 2000; Shen et al., 2011). Several products are found on the marketplace 295 
which are composed of Recaldent
TM
 these include Trident white sugar gum, Recaldent
TM
 sugar 296 
free gum, Recaldent mints
TM
 and MI Paste or Tooth mousse (Azarpazhooh & Limeback, 2008; 297 
Gupta & Prakash, 2011). CPP-ACP is understood to act through localising Ca and phosphate 298 
ions in the plaque and via their buffering capacity properties (Kitasako et al., 2010; Reynolds, 299 
Cai, Shen, & Walker, 2003). Despite the large amount of promising data generated from in vitro, 300 
in situ and also in vivo studies, contradictory results are also found in the scientific literature 301 
(Nongonierma & FitzGerald, 2012; Peters, 2010), suggesting no beneficial effect of CPPs as 302 
anticariogenic agents in humans (Altenburger, Gmeiner, Hellwig, Wrbas, & Schirrmeister, 2010; 303 
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Beerens, van der Veen, van Beek, & ten Cate, 2010; Brochner et al., 2011). This may be linked 304 
to the set-up of the human trials, i.e., differences in CPP dose, residence time, treatment applied 305 
to the control group and CPP interactions with other components (Nongonierma & FitzGerald, 306 
2012). 307 
The presence of CPPs in the GIT of humans has been demonstrated (Hartmann & Meisel, 2007; 308 
Meisel et al., 2003). CPPs were detected at higher concentrations following the ingestion of milk 309 
compared to that of CPPs. It was concluded that milk proteins may have a protective effect 310 
preventing further degradation of CPPs in the digestive tract (Meisel et al., 2003). A limited 311 
number of human studies carried out with CPPs have evaluated their mineral bioavailability 312 
enhancement effects. Ca and Zn absorption was evaluated in 22 young adults (20-30 y) in the 313 
presence of CPPs and commercial whole grain or rice-based cereal infant products (Hansen et 314 
al., 1997). Although no effect was seen for fractional Ca absorption in the presence of CPPs with 315 
the rice meal, differences in the absorption (+30%) was reported. There was an increase in Zn 316 
fractional absorption and Zn absorption in the presence of CPPs with rice. No significant effect 317 
of CPPs on fractional absorption and absorption of Ca and Zn was seen with the whole cereal, 318 
possibly due to the presence of phytates (Hansen et al., 1997). Similarly, another human study 319 
conducted with 31 adults (19–30 y) ingesting white bread with different levels of Ca and 320 
phytates did not show any positive role of CPPs on Ca and Zn absorption (Hansen et al., 1997). 321 
This lack of an effect of CPPs on the bioavailability of dietary Ca and Zn may arise from 322 
different factors such as the instability of the CPPs during digestion or an inadequate dosage of 323 
the CPPs. 324 
Radioisotopically labelled milk supplemented with CPP bound Fe (Fe--CN f(1-25)) or a control 325 
Fe (FeSO4) was administered once to 10 young females (20-30 y). There was a significant 326 
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increase in tissue (liver, spleen and sacrum) Fe uptake but not its absorption with Fe--CN f(1-327 
25) compared to FeSO4 (Ait-Oukhatar et al., 2002). Another in vivo study consisted of a 328 
randomised trial with 15 human subjects which were administered Ca lactate drinks with or 329 
without CPPs (control). The true fractional Ca absorption (TFCA, representing the proportion of 330 
Ca in the urine relative to that ingested) differed between the groups. Surprisingly, there was a 331 
decrease in the TFCA in the test groups receiving two different types of commercially available 332 
CPP preparations (TFCA = 22.7 and 23.5) compared to that of the control (TFCA = 26.0) group 333 
(Teucher et al., 2006). CPPs did not further enhance Ca absorption in healthy adults (25–36 y) as 334 
compared to a control milk drink (López-Huertas et al., 2006). Similar results were obtained 335 
with post-menopausal women, showing no effect of CPP supplementation on Ca absorption 336 
(Narva, Karkkainen, Poussa, Lamberg-Allardt, & Korpela, 2003). The effect of night time 337 
consumption of fermented milk supplemented with Ca and Ca enhancers (inulin type fructans-338 
ITF and CPPs) on bone resorption was studied in 85 post-menopausal women (Adolphi et al., 339 
2009). In the presence of ITF and CPPs, an increase in urinary Ca excretion was seen, which was 340 
linked with an enhanced Ca absorption. It was shown that CPP supplementation was effective in 341 
increasing Ca bioavailability in post-menopausal women with low Ca absorption in contrast with 342 
women with a high Ca absorption. However, the Ca enhancers did not further improve the 343 
reduced bone resorption observed following the consumption of fermented milk (Heaney, Saito, 344 
& Orimo, 1994). The different effects of CPPs on mineral bioavailability in humans could be 345 
explained by the presence of chelating agents (i.e. phytates, oxalates and tannins), the food 346 
matrix, CPP preparation, CPP dose and CPP:mineral ratio (Erba, Ciappellano, & Testolin, 2002; 347 
FitzGerald, 1998; FitzGerald & Meisel, 2003a; Gueguen & Pointillart, 2000; Meisel & 348 
FitzGerald, 2003; Meisel & Frister, 1988) as well as the health status of the human subjects, i.e., 349 
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in terms of mineral deficiencies (Adolphi et al., 2009), Ca malabsorption (Heaney et al., 1994) 350 
and Vit D levels (Narva et al., 2003). 351 
5 Antidiabetic peptides 352 
Consumption of milk protein–derived BAPs have been linked with serum glucose regulatory 353 
properties in humans. Different mechanisms may include an insulinotropic activity, incretin 354 
secretagogue action, as well as activity on different metabolic enzymes involved in the regulation 355 
of serum glucose such as dipeptidyl peptidase IV (DPP-IV), -amylase and -glucosidase 356 
(Lacroix & Li-Chan, 2014). No in vivo data appears to have been reported to date on the DPP-IV 357 
and -glucosidase inhibitory activity of milk protein hydrolysates in humans. To our knowledge, 358 
milk protein hydrolysates have mostly been shown to regulate serum glucose in humans through 359 
their insulinotropic activity. The individual components which are responsible for this 360 
insulinotropic activity of milk protein hydrolysate have not been clearly identified in humans. It 361 
is thought that the active components may comprise a combination of branched-chain amino 362 
acids (BCAA) and milk protein-derived peptides (Luhovyy, Akhavan, & Anderson, 2007; 363 
Morifuji et al., 2010). Free amino acids can directly act at the -cell level to release insulin 364 
through various mechanisms including membrane depolarisation, mitochondrial signalling 365 
affecting insulin secretion, etc. (Newsholme, Gaudel, & McClenaghan, 2010). 366 
The insulinotropic properties of milk-derived components have been particularly attributed to 367 
whey-derived peptides (Frid, Nilsson, Holst, & Björck, 2005; Luhovyy et al., 2007; Oseguera-368 
Toledo, González de Mejía, Reynoso-Camacho, Cardador-Martínez, & Amaya-Llano, 2014). 369 
However, it has been shown that both whey protein hydrolysates (WPHs) and casein 370 
hydrolysates (CNHs) are able to induce an insulinotropic response in humans. Most milk protein-371 
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derived hydrolysates which have been evaluated in humans appear to exist as proprietary 372 
products. In contrast, a human trial was recently conducted with a whey protein isolate (WPI) 373 
hydrolysate generated at a laboratory-scale with Flavourzyme
TM
 (Novozymes Japan, Chiba, 374 
Japan) (Goudarzi & Madadlou, 2013). The insulinotropic effects of milk protein hydrolysates 375 
have been seen both with (Frid et al., 2005; Geerts et al., 2011; Luhovyy et al., 2007) or without 376 
carbohydrates (Akhavan et al., 2010; Morifuji et al., 2010; Power, Hallihan, & Jakeman, 2009) 377 
and in the absence or presence of Leu (Geerts et al., 2011; Manders, Koopman, et al., 2006; 378 
Manders, Praet, et al., 2006), an amino acid which has been shown to have a strong 379 
insulinotropic activity. 380 
The insulinotropic activity of WPHs has been related to intestinal amino acid absorption and the 381 
increased plasma concentration of free amino acids (Leu, Ile, Phe, Arg, Tyr, Thr, Val, Ala and 382 
Lys), BCAA-containing dipeptides (e.g. Ile-Leu, Leu-Leu and Val-Leu) and possibly cyclic 383 
dipeptides (Koopman et al., 2009; Morifuji et al., 2010; Stanstrup et al., 2014; van Loon, Saris, 384 
Verhagen, & Wagenmakers, 2000). Contradictory results exist, where no direct correlation 385 
between plasma BCAA and the consumption of an insulinotropic WPH could be established 386 
(Power et al., 2009). Consumption of 10 g of a commercial WPH (Hilmar
TM
 8350; Hilmar 387 
Ingredients, Canada) by humans did not induce a reduction in post-meal serum glucose although 388 
insulin secretion was increased (Akhavan et al., 2010). This was explained by the fact that the 389 
WPH did not affect gut hormone secretion (i.e., cholecystokinin - CCK, glucagon-like peptide 1 390 
- GLP-1 and gastric inhibitory polypeptide - GIP) and consequently gastric emptying. In 391 
addition, the response observed in humans with various WPHs is possibly dependent on their 392 
free amino acid and peptide composition. The extent of protein hydrolysis may dictate in vivo 393 
plasma amino acid level following ingestion of protein hydrolysates (Morifuji et al., 2010). A 394 
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dose-response for insulin secretion was shown with a WPH generated at a laboratory-scale 395 
(Goudarzi & Madadlou, 2013). WPH doses  0.1 g/kg, did not induce an insulinotropic response 396 
in humans. The higher dose tested for WPH (0.4 g/kg) was associated with a reduction in the 2 h 397 
post-prandial serum glucose concentration (< 7.8 mM) (Goudarzi & Madadlou, 2013). 398 
Most of the in vivo work with CNHs appears to have been carried out with the proprietary CNH 399 
InsuVida
TM
 previously named Insuvital
TM
 (DSM, Delft, The Netherlands). Different doses of 400 
CNH were tested with or without carbohydrates and with or without free amino acids (Leu and 401 
Phe). The outcomes of the 7 human interventions carried out with InsuVida
TM
 are summarised in 402 
Table 3. Most of the studies carried out to date have shown a beneficial effect of the CNH on the 403 
reduction of serum glucose in type 2 diabetic (T2D) subjects (Geerts et al., 2011; Manders et al., 404 
2014; Manders, Koopman, et al., 2006; Manders et al., 2005; Manders, Praet, et al., 2006). In 405 
contrast, no significant effect of the CNH was found in two studies. In one case this was related 406 
to the relatively low amount (6 g) of CNH ingested (Jonker et al., 2011). In the second study, a 407 
relatively high dose (0.4 g/kg) of CNH was ingested (Manders, Praet, Vikstrom, Saris, & van 408 
Loon, 2007). The reasons behind the lack of an observed reduction in serum glucose in the study 409 
of Manders et al. (2007) are not clearly understood. Lower doses of the CNH have been tested in 410 
humans with the rationale of reducing high protein loads which may be detrimental to T2D 411 
subjects who are at risk of renal complications. Reducing the ingested dose (15 g) of CNH by 412 
half as compared to previous studies (Manders, Koopman, et al., 2006; Manders, Praet, et al., 413 
2006) still resulted in a reduction in serum glucose (Geerts et al., 2011). Similarly, reduction of 414 
the CNH dose to 12 g induced a reduction in serum glucose, however, this was not seen on 415 
ingestion of 6 g CNH (Jonker et al., 2011). Addition of Leu to the CNH induced a large increase 416 
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in plasma insulin concentration but only had a minor impact on postprandial serum glucose level 417 
(Geerts et al., 2011; Manders, Koopman, et al., 2006). 418 
6 Satiating peptides 419 
The development of new solutions to combat obesity is necessary due to the global increase in 420 
obesity incidence and its link with health complications including dyslipidemiae, CVD, impaired 421 
glucose metabolism, etc. (Gustafson, McMahon, Morrey, & Nan, 2001; Nguyen et al., 2012; 422 
Schrezenmeir & Jagla, 2000; WHO, 2013b). Reducing food intake and/or increasing energy 423 
expenditure are a means to control body weight. A reduction of food intake may be facilitated by 424 
increasing satiety. Satiety, which arises from various signals between the gut and brain, 425 
corresponds to the hunger alleviation seen after food intake. It is thought to involve stimulation 426 
of gut hormone (CCK, peptide YY (PYY) and GLP-1) receptors, a slower gastric emptying, an 427 
increased diet-induced thermogenesis and possibly opioid receptors (Anderson & Moore, 2004; 428 
Bendtsen, Lorenzen, Bendsen, Rasmussen, & Astrup, 2013; Luhovyy et al., 2007; McGregor & 429 
Poppitt, 2013; Sam, Troke, Tan, & Bewick, 2012; Turgeon & Rioux, 2011). 430 
In terms of direct intake of milk protein-derived peptides, particular attention has been given to 431 
CMP. The satiating properties of CMP have been considered to involve an increased release of 432 
CCK and inhibition of gastric secretions (Guilloteau et al., 2010; Gustafson et al., 2001; Thomä-433 
Worringer, Sørensen, & López-Fandiño, 2006; Yvon, Beucher, Guilloteau, Le Huerou-Luron, & 434 
Corring, 1994). However, most human studies conducted to date with CMP appear to have failed 435 
to demonstrate a clear satiating effect followed by a reduction in food intake (Chungchunlam, 436 
Henare, Ganesh, & Moughan, 2014; Gustafson et al., 2001; Poppitt, Strik, McArdle, McGill, & 437 
Hall, 2013; Yvon et al., 1994). This was also the case in the study conducted by Keogh et al. 438 
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(2010) showing no significant effect of a CMP preload (50 g) on plasma CCK level, food intake 439 
and subjective satiety in obese subjects compared to a glucose control. Similarly, CMP alone 440 
used as a preload before a meal did not reduce food intake in healthy humans (Chungchunlam et 441 
al., 2014). Although a CMP preload failed to increase pre-test meal satiety, a positive role of 442 
CMP on compensatory food intake (additional food intake throughout the day) has been shown 443 
in females in contrast with male subjects (Burton-Freeman, 2008). This was evidenced by a 444 
significant decrease in food intake on the study day. The differences between male and female 445 
subjects could be linked to the fact that hormonal changes also differed, with pre-lunch CCK 446 
concentration being twice as high in women as in men. Differences in human satiety study 447 
outcomes may arise from various factors including the metabolic/health status of the individuals 448 
participating in the study, their age, sex, the timing of the satiety evaluation and also the quality 449 
and amount of protein ingested. The emotional status of the subjects is also a very important 450 
parameter in food intake (Raspopow, Abizaid, Matheson, & Anisman, 2014). 451 
7 Immunomodulatory and antimicrobial peptides 452 
The consumption of milk proteins has been associated with immunostimulatory effects in 453 
humans. A reduction in low-grade inflammation in healthy adults was correlated with the intake 454 
of dairy products in the ATTICA study (18 months, 3042 subjects) (Panagiotakos, Pitsavos, 455 
Zampelas, Chrysohoou, & Stefanadis, 2010). It is not clear, however, if the origin of this effect 456 
was the milk protein components. CPPs (290 mg mixture of β-CN f(1-28) and αs2-CN f(1-32)), 457 
formulated in cakes, were ingested for 30 days by 7 healthy subjects. Immunostimulatory effects 458 
were seen, with higher faecal IgA levels compared to the control group (Kitamura & Otani, 459 
2002). Studies with a commercial WPH (MEIN
TM
, Meiji Dairies Co., Tokyo, Japan) have shown 460 
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a significant reduction in inflammatory markers (high-sensitivity C-reactive protein (hsCRP), IL-461 
6, IL-8, and tumour necrosis factor (TNF)-α) after 12 weeks consumption in elderly patients 462 
participating in a low-exercise programme and presenting chronic obstructive pulmonary disease 463 
(Sugawara et al., 2012). 464 
Antimicrobial and immunostimulatory activities are linked. For instance, specific milk protein-465 
derived BAPs with immunomodulatory action have been shown to increase the resistance to 466 
pathogens in the GIT (Gauthier, Pouliot, & Saint-Sauveur, 2006). Various milk proteins and 467 
peptides have been reported to have a wide range of antimicrobial properties in vitro (Agyei & 468 
Danquah, 2012; Benkerroum, 2010; Hartmann & Meisel, 2007; Morris & FitzGerald, 2009; 469 
Wilson, Buchanan, Allan, & Tikoo, 2012). Specific modes of action, involving their buffering 470 
capacity and inhibitory activity on microbial enzymes, have been proposed for the antibacterial 471 
activity of CPPs (Rose, 2000). A few studies involving in situ experiments with humans wearing 472 
dental appliances showed that CPP-ACP could increase the pH (from 5.0 to 5.8) through its 473 
buffering capacity, following a carbohydrate challenge (Caruana, Al Mulaify, Moazzez, & 474 
Bartlett, 2009). Another human intervention study evaluated the effect of CPP-amorphous 475 
calcium phosphate fluoride (ACPF) on bacteria growth in white spot lesions found after 476 
debonding of orthodontic appliances. It was shown after 4 weeks of topical treatment with CPP-477 
ACPF that there was a reduction in aciduric bacteria (from 47.4 to 38.1%) and Streptococcus 478 
mutans (from 9.6 to 6.6%) counts (Beerens et al., 2010). In contrast, no significant effect of 479 
CPP-ACP could be found in humans wearing fixed orthodontic appliances (Marchisio, Esposito, 480 
& Genovesi, 2010). 481 
Peptides originating from LF have also been shown to have a wide range of antimicrobial and 482 
anti-inflammatory activities in vivo, notably human LF f(1-11) (Brouwer et al., 2011). This 483 
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peptide has also been evaluated for safety in humans. It was reported to be safe (no adverse 484 
effects on various health markers or cytotoxicity) in healthy humans and in haematopoietic stem 485 
cell transplantation patients in intravenous doses as high as 5000 μg over 5 days (van der Velden 486 
et al., 2009). However, its pharmacokinetics are unknown, this has been attributed to analytical 487 
limitations where detection of the peptide in the plasma was not possible due to the very low 488 
doses employed ( 5000 µg) (van der Velden et al., 2009). 489 
8 Other bioactivities 490 
8.1 Opioid peptides 491 
Opioid peptide sequences typically contain Tyr-Gly-Gly-Phe at their N-terminal side and in the 492 
case of atypical opioid peptides, a Tyr residue is found at the N-terminus (Teschemacher, Koch, 493 
& Brantl, 1997). These peptides have been reported to behave like morphine in the brain. These 494 
have been found within milk proteins, both in CN (caseinomorphins) and WP (lactorphins). 495 
Although numerous small animal studies have been carried out with milk protein-derived BAPs 496 
with opioid activity, they do not appear to have been extensively evaluated in humans (Artym & 497 
Zimecki, 2013; Teschemacher et al., 1997). In addition, in an EFSA opinion report, the clinical 498 
evidence to date of the potential role of -casomorphin 7 (-CN f(60-66)) on various health 499 
conditions has been judged to be inconclusive especially since no dose-effect relationship 500 
appears to have been reported in the literature (De Noni et al., 2009). 501 
Following ingestion of milk/dairy products, opioid peptides have been detected in different parts 502 
of the body including the GIT of humans (Svedberg, de Haas, Leimenstoll, Paul, & 503 
Teschemacher, 1985), the brain (Nyberg et al., 1989; Pasi, Mahler, Lansel, Bernasconi, & 504 
Messiha, 1993) and different body fluids of infants and adults (Koch et al., 1988; Kost et al., 505 
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2009; Renlund et al., 1993; Righard et al., 2014). Human -casomorphin-8 ((-CN f(51-58)) 506 
could be detected in the milk of a lactating human female suffering from post-partum depression 507 
(Renlund et al., 1993). Similarly, fragments originating from human -casomorphin-8 were 508 
identified in the plasma of women during pregnancy and post-parturition (Koch et al., 1988). 509 
Other studies have reported high levels of human -casomorphin-8 in the sera of women 510 
suffering from post-partum depression (Righard et al., 2014). In addition, elevated levels of 511 
human -casomorphin-8 both in the milk and human sera of women presenting signs of mastitis 512 
have also been detected (Righard et al., 2014). These levels were reduced when the infection was 513 
cleared up. Therefore, it has been proposed that there was a relationship between human β-514 
casomorphin-8 concentration in physiological fluids, mastitis, and post-partum depression 515 
(Righard et al., 2014). It has been suggested that -casomorphin-8 originating from human milk 516 
is able to reach the circulation and the brain owing to its hydrophobic character (Pasi et al., 1993; 517 
Renlund et al., 1993). A connection between -casomorphin and schizophrenia, autism and 518 
apnoea in sudden infant death syndrome has also been proposed (Kamiński, Cieślińska, & 519 
Kostyra, 2007; Sun et al., 2003). However, to date the clinical evidence does not appear to be 520 
clear in this regard (De Noni et al., 2009; Sun et al., 2003). Similarly, human ((-CN f(51-57)) 521 
and bovine -casomorphin-7 could be detected in the plasma of infants (< 1 y) fed with breast 522 
milk or cow’s milk infant formulae (Kost et al., 2009). -Casomorphin-7 fragments were 523 
identified in the plasma both in the pre- and postprandial phase. A positive correlation was 524 
reported with the elevated plasma levels of human -casomorphin-7, normal psychomotor 525 
development and muscle tone. Human -casomorphin-7 was reported to be twice as high in 526 
infants with normal functions as compared with infants at risk of developmental delay and 527 
increased muscle tone. In contrast, it was the opposite for bovine -casomorphin-7 (Kost et al., 528 
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2009). -Casomorphin-7 can be generated from -CN variants A1 and B but not from the A2 529 
variant. Some studies have suggested a link between the onset of type 1 diabetes, ischaemic heart 530 
disease, autism, schizophrenia, and -casomorphin-7 (Elliott, Harris, Hill, Bibby, & Wasmuth, 531 
1999; Laugesen & Elliott, 2003). A role of milk protein-derived peptides in satiety and 532 
hypertension, possibly involving opioid receptor agonism effects, has also been proposed 533 
(Froetschel, Azain, Edwards, Barb, & Amos, 2001; Nurminen et al., 2000). However, to date, 534 
there is no conclusive evidence for these effects in humans (De Noni et al., 2009). 535 
8.2 Antioxidant peptides 536 
While a large amount of information is available in the literature reporting the antioxidant 537 
activity of milk BAPs in vitro, there is limited evidence showing these effects in humans (Power 538 
et al., 2013). The link between in vitro and in vivo antioxidant capacities has not been clearly 539 
established (Lacroix & Li-Chan, 2014). Furthermore, the anti- or pro-oxidant mechanisms of 540 
milk protein-derived BAPs is not fully understood (Pihlanto, 2006). The antioxidant properties of 541 
milk peptides have mostly been investigated in the context of physical exercise. Reactive oxygen 542 
species (ROS) generated by respiratory metabolism may lead to muscle inflammation, fatigue 543 
and reduced post-exercise performance. A recent study was conducted with elite Brazilian soccer 544 
players who were supplemented with a whey protein concentrate (WPC) hydrolysate (0.5 g 545 
protein/kg of body mass/day) for 12 weeks (Lollo et al., 2014). WPC hydrolysate 546 
supplementation led to a decrease in creatine kinase (CK; -42%) and lactate dehydrogenase 547 
(LDH; -38%), which are in vivo markers of oxidative stress and tissue damage (Lollo et al., 548 
2014). 549 
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8.3 Populations with specific needs: allergy and phenylketonuria (PKU) 550 
Hydrolysed milk proteins are used as ingredients in different nutritional formulations for 551 
populations with specific nutritional needs. These comprise infants with cow’s milk protein 552 
allergy (CMPA) and people suffering from PKU. The aim of milk protein hydrolysis includes the 553 
destruction of allergenic epitopes (CMPA formulation), an increased digestibility of the proteins 554 
or the generation of ingredients with low Phe levels for PKU sufferers. 555 
Oral tolerance is defined as a stimulation of type 1-regulatory T (Tr-1) cells leading to an 556 
immune response suppression involving IL-10 secretion (Adel-Patient et al., 2012; Adel‐Patient 557 
et al., 2011; Gauthier et al., 2006; Prioult, Pecquet, & Fliss, 2004). The utilisation of infant 558 
formulae containing partially or extensively hydrolysed milk proteins is used in order to reduce 559 
allergenic milk protein epitopes,(Berg, 2013; Elsayed, Hill, & Do, 2004; Zheng, Shen, Bu, & 560 
Luo, 2008). 561 
PKU is a genetic metabolic disorder characterised by a phenylalanine hydrolase (the enzyme 562 
responsible for the conversion of Phe to Tyr) malfunction or deficiency (Clemente, 2000; Ney et 563 
al., 2009). CMP is free from Phe residues. Therefore, it is an interesting protein-based ingredient 564 
for use in the formulation of food products for PKU nutrition (Ney et al., 2009; Soltanizadeh & 565 
Mirmoghtadaie, 2014). Another alternative is the generation of milk protein hydrolysates with 566 
reduced Phe levels. In order to prepare these formulae, the first step consists in enzymatic 567 
hydrolysis of milk proteins to release Phe, followed by Phe removal with adsorbent resins. 568 
Depending on the processing conditions, Phe removal efficiencies ranging from 69 to 99% may 569 
be attained (Cogan, Moshe, & Mokady, 1981; López-Bajonero, Lara-Calderón, Gálvez-Mariscal, 570 
Velazques-Arellano, & López-Munguia, 1991; Silva, De Marco, Afonso, Lopes, & Silvestre, 571 
2007; Silvestre et al., 2013; Silvestre, Silva, Silva, Silva, & Amorin, 2011). 572 
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9 Conclusions and perspectives on the efficacy of milk BAPs in humans 573 
The physiological effects of milk protein-derived BAPs have been studied in humans for many 574 
decades. Analysis of human fluids and tissues has been made easier with the development of 575 
analytical techniques such as MS, the improvement of detector sensitivity (Panchaud et al., 576 
2012) and the development of software which allow treatment of large amounts of data (Iwaniak, 577 
Minkiewicz, Darewicz, Protasiewicz, & Mogut, 2015). Despite these scientific advances and 578 
increasing knowledge on the structure-function activity relationship of BAPs, there is still a high 579 
level of uncertainty on the role of milk BAPs in human health. Many reasons for this have been 580 
identified during the compilation of data for this review. In particular, when analyzing EFSA 581 
opinions on specific BAPs, it appears that the main reason for negative opinion lies in the poor 582 
characterization of the BAPS, the lack of dose-response relationships, the low bioavailability of 583 
the peptides and their low-potency (De Noni et al., 2009; EFSA, 2010, 2011). 584 
Although the proteome of milk proteins has been well characterized, the peptide composition of 585 
the resultant hydrolysates may be difficult to determine. This may be linked to the fact that the 586 
identification of short peptides (< 5 amino acid residues) within complex milk protein 587 
hydrolysates still represents a technical challenge (Le Maux et al., 2015; Panchaud et al., 2012). 588 
However, many of these short peptides are thought to play a major role in the bioactive 589 
properties associated with milk BAPs. The lack of detailed information on the identity of the 590 
active components within hydrolysates may also be due to the fact that these cannot be easily 591 
identified and quantified in physiological fluids. In addition, because milk protein hydrolysates 592 
are composed of a large number of peptides, it may be quite difficult to attribute a specific 593 
physiological effect to a particular peptide. Furthermore, due to their low complexity, short 594 
peptides may be found within a wide range of different food proteins and possibly within 595 
 31 
 
endogenous proteins. Recently, gut endogenous proteins (originating from saliva, gastric 596 
secretions, bile, pancreatic secretions, mucins, epithelial cells, plasma proteins and the 597 
microbiota) have been suggested as a potential source of BAPs in humans (Moughan, 598 
Rutherfurd, Montoya, & Dave, 2013). These gut endogenous protein–derived peptides may be 599 
released in amounts twice as high as those arising from the diet (Dave, Montoya, Rutherfurd, & 600 
Moughan, 2014; Moughan et al., 2013). It was suggested using an in silico digestion approach 601 
that certain gut endogenous proteins could yield peptides which had the same structure as 602 
previously identified BAPs, including ACE inhibitory peptides (Dave et al., 2014). Given that 603 
BAPs may also be generated from endogenous proteins, this highlights the difficulty of including 604 
relevant human controls in human interventions. Many other confounding factors may negatively 605 
affect the outcomes of human intervention studies, including external (e.g. the diet, environment, 606 
etc.) and internal (the genotype, health status, microbiota, body composition, psychological and 607 
nutritional status, etc.) factors. It is then understandable why elucidating the role of BAPs in 608 
humans is more challenging when compared to drug compounds which are normally not present 609 
within the human body. In order to measure significant differences between the control and the 610 
test subject groups, it appears critical that the intervention with the test compound(s) allows a 611 
significant increase in BAP concentration in vivo. In this context, an increase in the 612 
bioaccessibility and bioavailability of BAPs may help in enhancing the concentration of the BAP 613 
at the target organ/receptor. 614 
Intestinal absorption of peptides has been reported to involve a transcellular 615 
(endocytosis/transcytosis) or paracellular route (Fernández-Musoles et al., 2013; Gardner, 1983; 616 
Jahan-Mihan, Luhovyy, El Khoury, & Anderson, 2011). The BAP concentrations identified in 617 
the GIT (Boutrou et al., 2013; Ledoux et al., 1999; Meisel et al., 2003), sera and plasma (Table 618 
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1; Chabance et al., 1998; Foltz et al., 2007) of humans has been deemed sufficient to mediate 619 
bioactivity in vivo. However, a low bioavailability for BAPs has been reported, possibly due to 620 
the extensive degradation of the peptides (> 90%) occurring in the intestine, notably during 621 
permeation (Jahan-Mihan et al., 2011). Further processing of BAPs by intestinal and serum 622 
peptidases may be responsible for a low bioavailability, which can constitute a limiting factor, 623 
explaining the limited potential of BAPs in humans (Gardner, 1983). Different studies have 624 
investigated ways to enhance delivery of bioactive components in humans. Increasing the dose of 625 
BAP ingested may help to increase their bioavailability. However, this strategy may induce high 626 
costs and cause sensory defects (e.g. bitterness) with low/limited benefits for the biological 627 
outcomes. Another alternative is the utilization of microencapsulation strategies (Barbosa et al., 628 
2004; Brayden & Baird, 2013; de Vos, Faas, Spasojevic, & Sikkema, 2010; Morais et al., 2004; 629 
Onwulata, 2012; Yang et al., 2012). An additional advantage of microencapsulation of milk 630 
protein hydrolysates is the bitterness masking effect and potential increased stability during 631 
storage (Favaro-Trindade, Santana, Monterrey-Quintero, Trindade, & Netto, 2010; Rocha, 632 
Trindade, Netto, & Favaro-Trindade, 2009; Subtil et al., 2014). Paracellular and transcellular 633 
enhancers also exist which may improve the bioavailability of peptides. However, due to safety 634 
concerns, these are not currently being used in humans (Maher & Brayden, 2012). 635 
On assessing the scientific evidence linking the positive role of milk protein BAPs on human 636 
health, several studies appears to show a positive effect in certain health conditions. However, in 637 
many instances, this effect is lower than that observed with pharmaceutical drugs. To date, two 638 
EFSA opinions on the role of the milk BAPs (C12 peptide and LTPs) and the reduction of BP in 639 
humans have been published. The C12 peptide claims were rejected on the basis that it was 640 
insufficiently characterised in the products which were fed to the subjects during the human 641 
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trials. In addition, there was no direct relationship between the maintenance of a normal BP and 642 
the administration of the C12 peptide (EFSA, 2010). Similarly, a negative opinion was given for 643 
the effect of the LTPs on BP reduction in humans (EFSA, 2011). Although the peptides were 644 
sufficiently characterised, it was estimated that certain human studies presented methodological 645 
limitations (inadequately powered studies, treatment allocation, randomisation, blinding and 646 
statistical treatment). Therefore, the outcomes of the meta-analyses provided in support of the 647 
dossier to EFSA were not taken into account. In addition, because no clear mechanism of action 648 
was proposed to explain the effects seen at the doses tested, a negative opinion was delivered for 649 
LTPs. 650 
A few recommendations may be proposed to improve the quality of the scientific data generated 651 
in human intervention studies with milk BAPs. It appears evident from the contradictory results 652 
with BAP-based ingredients that there is a real need to establish universal guidelines for the 653 
evaluation of these BAPs in humans. Several studies have highlighted the fact that certain 654 
subjects are non-responders to the treatment applied (Usinger, Jensen, Flambard, Linneberg, & 655 
Ibsen, 2010), which may in certain instances involve the nature of their gut microbiota (Flint, 656 
Scott, Louis, & Duncan, 2012; Norheim et al., 2012). In addition, interindividual differences 657 
exist in the digestion of food proteins in humans (Boutrou et al., 2013; Moughan et al., 2013). 658 
Human studies need to take these aspects into consideration in order to draw adequate 659 
conclusions on the outcomes of the interventions with milk BAPs. In addition, it appears that 660 
certain studies are underpowered from a statistical point of view, which has detrimental 661 
consequences on the scientific quality of some of the data published to date. For example, in 662 
their meta-analysis on BP reducing LTP, Cicero et al. (2013) calculated that a population of 663 
1,000 subjects would be required for a study powered at 80% with a 5%  risk. Although it 664 
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appears challenging to design studies with such a large number of subjects, meta-analyses (larger 665 
population groups taken into account) may help to overcome this limitation. However, the 666 
human studies included in meta-analyses are not always conducted under the same conditions 667 
(dose, duration, population, etc.). Double-blind randomised clinical trials have been suggested 668 
for a better design of human interventions (Qin et al., 2013). Consensus methodologies are also 669 
needed in terms of the analytical tools employed to adequately identify and quantify BAPs in 670 
biological tissues and fluids. This may help to develop better designed human intervention 671 
studies and provide case studies with sufficient scientific evidence to support health claims as 672 
this is a requirement with numerous national and international health agencies such as EFSA, 673 
which grants positive opinions on the basis of human intervention and structure-activity 674 
relationship outcomes (Jäkälä & Vapaatalo, 2010; Lalor & Wall, 2013). 675 
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Table 1. Peptide sequences detected in human biological fluids (plasma, serum and milk) following the ingestion of bovine milk or 
dairy products. 
Parent 
protein 
Peptide fragment Peptide sequence
1
 Locus Bioactive 
properties 
Reference 
s1-CN 1-21 RPKHPIKHQGLPQEVLNENLL plasma n.d. (Chabance et al., 1998) 
 1-23 RPKHPIKHQGLPQEVLNENLLRF 
(isracidin) 
plasma antibacterial (Chabance et al., 1998) 
-CN 51-58 YPFVEPIP (human -casomorphin-8) plasma opioid (Koch et al., 1988) 
 51-58 YPFVEPIP (human -casomorphin-8) milk opioid (Renlund et al., 1993) 
 51-58 YPFVEPIP (human -casomorphin-8) serum & milk opioid (Righard et al., 2014) 
 51-57 YPFVEPI (human -casomorphin-7) plasma opioid (Kost et al., 2009) 
 60-66 YPFPGPI (bovine -casomorphin-7) plasma opioid (Kost et al., 2009) 
-CN 106-117 MAIPPKKNQDKT plasma n.d. (Chabance et al., 1998) 
 106-169 Glycomacropeptide plasma antithrombic (Chabance et al., 1995) 
LF 81-82 & 399-400 IY serum ACE inhibitor (Foltz et al., 2007) 
CN and whey diverse LW serum ACE inhibitor (Foltz et al., 2007) 
 diverse FY serum ACE inhibitor (Foltz et al., 2007) 
 diverse 
(-La & BSA) 
IW serum ACE inhibitor (Foltz et al., 2007) 
 diverse AW serum ACE inhibitor (Foltz et al., 2007) 
 diverse VY serum ACE inhibitor (Foltz et al., 2007) 
 diverse 
(- and -CN) 
IPP serum ACE inhibitor (Foltz et al., 2007) 
 diverse LPP serum ACE inhibitor (Foltz et al., 2007) 
 diverse IL plasma n.d. (Morifuji et al., 2010) 
 diverse VL plasma n.d. (Morifuji et al., 2010) 
 diverse LL plasma n.d. (Morifuji et al., 2010) 
 
1
Peptide sequence with the one letter amino acid code; n.d.: not disclosed; ACE: angiotensin converting enzyme; BSA: bovine serum albumin; 
CN: casein; -La: -lactalbumin; LF: lactoferrin. 
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Table 2. Summary of the meta-analyses carried out with lactotripeptides (LTPs; Val-Pro-Pro and Ile-Pro-Pro) with angiotensin 
converting enzyme (ACE) inhibitory properties: effect on blood pressure reduction in humans. 
Period of 
study 
Number of 
studies 
included 
Total number 
of participants 
Ethnicity LTP dose 
(mg/day) 
Average 
reduction of 
office blood 
pressure 
(mmHg)
1
 
Average 
reduction of 24 h 
ambulatory 
blood pressure 
(mmHg)
1
 
Reference 
1996-2005 9 (12 trials) 623 (♂ and ♀) Japanese & 
Europeans 
2.6–5.6 SBP: -4.8* 
DBP: -2.2
*
 
n.d. (Xu et al., 2008) 
1996-2010 19 1,532 (♂ and ♀) Japanese & 
Europeans 
2.0–10.2 SBP: -4.0* 
DBP: -1.9
*
 
n.d. (Turpeinen et 
al., 2013) 
1996-2010 18 1,691(♂ and ♀) Japanese & 
Europeans 
2-52 
(9.4±13.3) 
SBP: -3.73
*
 
DBP: -1.97
*
 
n.d. (Cicero et al., 
2011) 
1996-2011 28 (in 24 
papers) 
1,919 (♂ and ♀) Japanese & 
Europeans 
n.d. SBP: -1.66
*
 
DBP: -0.76
*
 
SBP: -1.30
*
 
DBP: -0.57
ns
 
(Qin et al., 
2013) 
1996-2012 33 (in 30 
papers) 
2,200 (1184 ♂ 
and 1016 ♀) 
Japanese & 
Europeans 
10.5 
(average) 
SBP: -2.95
*
 
DBP: -1.51
*
 
SBP: -0.94
ns
 
DBP: -0.46
ns
 
(Fekete et al., 
2015) 
2002-2012 14 (15 sets) 1,277 (♂ and ♀) Europeans 1.8-10.2 SBP: -1.28* 
DBP: -0.59
*
 
n.d. (Cicero et al., 
2013) 
 
DBP: diastolic blood pressure; SBP: systolic blood pressure; LTP: lactotripeptide; n.d.: not determined; ♂: males; ♀: females. 
1
Statistical significance of the results, 
*
: statistically different (P < 0.05) results compared to the control and 
ns
: not significantly different (P > 
0.05) from the control. 
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Table 3. Summary of the glycaemic management outcomes of the randomised double blind human studies conducted with the 
InsuVida
TM
 (DSM, Delft, The Netherlands) casein hydrolysate. 
Samples evaluated Human subjects In vivo outcomes Reference 
  % decrease of blood 
Glucose concentration
1 
% increase of blood insulin 
concentration
1 
 
(1) = 0.7 g/kg CHO 
(2) = (1) + 0.35 g/kg CNH 
mixed with Leu and Phe 
 
59-64 y ♂ 
T2D: 59 
Healthy: 9 
T2D: -15.12% 
Healthy: -92.97% 
T2D: 299  64% 
Healthy: 132  63% 
(Manders et al., 2005) 
(1) = 0.7g/kg CHO 
(2) = (1) + 0.3 g/kg CNH 
(3) = (2) +0.1 g/kg Leu 
 
57-62 y ♂ 
T2D: 10 
Healthy: 10 
T2D: -15 and -12% (for 
(2) and (3), respectively) 
Healthy: -92 and -97% 
(for (2) and (3), 
respectively) 
 
T2D: 41 and 204% (for (2) and 
(3), respectively) 
Healthy: 66 and 221% (for (2) and 
(3), respectively) 
 
(Manders, Koopman, et 
al., 2006) 
(1) = Placebo 
(2) = 0.3 g/kg CNH + 0.1 
g/kg Leu 
 
57-61 y 
T2D: 11 
Healthy: 11 
T2D: -11  3% 
Healthy: n.s. 
n.d. 
 
(Manders, Praet, et al., 
2006) 
(1) = Placebo 
(2) = 0.4 g/kg CNH 
 
60-64 y ♂ 
T2D: 13 
n.s. 
 
n.d. 
 
(Manders et al., 2007) 
 
(1) = Placebo 
(2) = 15 g CN 
(3) = 15 g CNH 
(4) = 15 g CNH + 5 g Leu 
 
50-70 y ♂ & ♀ 
T2D: 36 
T2D: -4.7% for (3) and 
(4); n.s. for (2) 
 
T2D: 26.1 and 51.8% for (3) and 
(4), respectively 
 
(Geerts et al., 2011) 
(1) = 50 g CHO 
(2) = (1) + 6 g CNH 
(3) = (1) + 12 g CNH 
57-59 y ♂  
T2D: 13 
T2D: n.s. effect with (2) 
and -6% (3) 
 
T2D: n.s. effect with (2) and 26% 
for (3) and (4), respectively 
 
(Jonker et al., 2011) 
 51 
 
 
(1) = 0.7 g/kg CHO 
(2) = (1) + 0.3 g/kg CN 
(3) = (1) + 0.3 g/kg CNH 
44-79 y ♂ 
T2D : 60 
T2D: -22 ± 32 and -23 ± 
36% for (2) and (3), 
respectively 
T2D: 99 ± 41 and 110 ± 10% for 
(2) and (3), respectively 
(Manders et al., 2014) 
 
CHO: carbohydrates; CN: casein; CNH: casein hydrolysate; n.d.: not determined; n.s.: not significant; T2D: type 2 diabetes; ♂: males; ♀: 
females. 
1
In each study, the percentage increase or decrease is expressed relatively to the control sample (1). 
 
 
